Ensysce Biosciences, Inc. short interest in 2025
In 2025, Ensysce Biosciences, Inc.'s disclosed short interest ran from 1.57% of shares outstanding on 14 Mar 2025 to 4.72% on 31 Dec 2025, a change of +3.15 percentage points. The year's high was 14.53% on 15 May 2025 and its low 1.57% on 14 Mar 2025, averaging 6.99% across 16 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 7.37 days on 30 Jun 2025. Full history: Ensysce Biosciences, Inc..
Cite this page
By year: 2022 · 2023 · 2024 · 2025 · 2026
2025 in figures
- Start of year
- 1.57% (14 Mar 2025)
- End of year
- 4.72% (31 Dec 2025)
- Change
- +3.15 pp
- High
- 14.53% (15 May 2025)
- Low
- 1.57% (14 Mar 2025)
- Average
- 6.99%
- Highest days to cover
- 7.37 (30 Jun 2025)
- SEC filings marked
- 8
Every report in 2025
| Settlement | Short interest | Days to cover | Filings since previous |
|---|---|---|---|
| 14 Mar 2025 | 1.57% | 1.27 | 10-K filed, results (8-K) |
| 31 Mar 2025 | 2.24% | 1.45 | |
| 15 May 2025 | 14.53% | 1.00 | 10-Q filed, results (8-K) |
| 13 Jun 2025 | 12.37% | 1.00 | |
| 30 Jun 2025 | 11.51% | 7.37 | |
| 15 Jul 2025 | 6.72% | 1.50 | |
| 31 Jul 2025 | 5.73% | 1.00 | |
| 15 Aug 2025 | 14.27% | 2.11 | 10-Q filed, results (8-K) |
| 29 Aug 2025 | 12.62% | 7.26 | |
| 15 Sep 2025 | 8.08% | 3.81 | |
| 30 Sep 2025 | 5.05% | 1.26 | |
| 15 Oct 2025 | 5.50% | 1.00 | |
| 31 Oct 2025 | 2.40% | 1.00 | |
| 14 Nov 2025 | 2.33% | 1.42 | 10-Q filed, results (8-K) |
| 28 Nov 2025 | 2.20% | 1.00 | |
| 31 Dec 2025 | 4.72% | 1.25 |
See also: Ensysce Biosciences, Inc.'s full history · most shorted US stocks of 2025 · today's US league.
About this data
US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.